<DOC>
	<DOCNO>NCT03100942</DOCNO>
	<brief_summary>The primary objective study assess efficacy filgotinib , GS-9876 , tirabrutinib ( formerly GS-4059 ) adult active Sjogren 's Syndrome ( SjS ) .</brief_summary>
	<brief_title>Safety Efficacy Study Filgotinib , GS-9876 Tirabrutinib Adults With Active Sjogren 's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<criteria>Key Diagnosed SjS accord American European Consensus Group ( AECG ) classification Active SjS define ESSDAI â‰¥ 5 Seropositivity antibody SjSassociated antigens A B ( antiSSA antiSSB ) Key Concurrent treatment biologic disease modify antirheumatic drug ( bDMARD ) ( prior bDMARD treatment allow appropriate washout per study protocol ) Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>